



Setting the Standard for Modern Dermatology Care

**\$60,000,000
Equity Offering**

Proactive Dermatology Group is building a leading dermatology group in the U.S. by acquiring successful practices in the Southeastern U.S.

Leveraging industry best practices and cutting-edge technology, PDG will improve acquired practices, deliver better care to patients, reduce the administrative burden on physicians, and deliver superior returns to investors.

Practices in diligence and negotiating purchase agreements and LOI's represent:

-  **350+ employees** in Florida and Georgia
-  **27 offices** in two top 20 MSA's in the U.S.¹
-  Over **\$55 million** in **revenue**
-  Over **\$8 million** in **practice EBITDA**
-  **\$125 million** in enterprise value²

PDG's additional acquisition pipeline includes another \$60+ million in revenue and \$11+ million of EBITDA.

Note: Statistics for two acquisitions expected to close July 31, 2020 and LOIs with two additional practices expected to close before September 30, 2020

1. Statista, Top twenty fastest growing MSAs in the U.S. from 2010 to 2019.

2. Estimated at 9/30/20 based on recent precedent transactions in the dermatology sector (~15x EBITDA).



DELIVERING HIGH QUALITY CARE

PDG will provide the full range of dermatology services – general, medical and cosmetic dermatology. In partnership with incredibly talented and passionate physicians, PDG is becoming the standard for modern dermatology care.

TAKING CARE OF PHYSICIANS

PDG leverages cutting-edge technology solutions to improve efficiency and evaluate opportunities to expand services or add staff. Deep insights and outstanding support mean doctors can focus on providing the best care to their patients.

TALENTED LEADERSHIP TEAM

Leadership team has over 100 years of combined medical practice management, executive leadership, entrepreneurship, investing, M&A, post-merger integration and compliance experience.

DERMATOLOGY IS A LARGE, GROWING AND STABLE MARKET

\$16 billion in
annual spending

2.3% est. compound annual
growth 2018 - 2021

Resilient

U.S. GDP



-4.3% growth
2007 - 2009

Dermatology



2.1% CAGR
2007 - 2009

PDG IS WELL POSITIONED FOR THE CURRENT ENVIRONMENT

DIVERSE REVENUE AND MARKETS

Focused on some of the most attractive markets in the U.S. Estimated Pro Forma LTM 9/30/20 Revenue of \$55 million will be split between Florida and Georgia.

Physicians provide a broad range of dermatology services including general, medical and cosmetic dermatology, Mohs surgery and superficial radiotherapy.

ESTABLISHED SYSTEMS AND INFRASTRUCTURE

Established systems and infrastructure to support rapid growth, including call center, billings and collections, internal pathology laboratory operations, an experienced technology team, among others.

TALENTED TEAM

Executive team has deep practice management, executive leadership, telemedicine, post-merger integration, compliance, and M&A experience having executed over \$40 billion in transactions, including roll-ups and distressed M&A transactions.

Team of 60+ top physicians and mid-levels.

VISIONARY PLAN

Pathway to scale to over \$200 million of revenue in three years, which will create tremendous benefit for all PDG's stakeholders and an enterprise value of \$500+ million¹.

1. Based on recent precedent transactions in the dermatology sector (~15x EBITDA).



PDG is seeking to raise \$60 million of equity to fund the cash portion of the acquisitions expected to close on or before September 30th and for general corporate purposes.

HIGHLIGHTS

**Clear Pathway to
\$500+ million Enterprise Value**

**Experienced,
Values-Driven Team**

**Significant Multiple
Expansion Opportunity**



**Insulated from the
Effects of COVID-19**

**Established Cost Containment
& Growth Strategies**

**Long-term Growing,
Stable Market**

Strictly Private & Confidential

This confidential overview (the "Teaser") contains certain information pertaining to Proactive Dermatology Group and its subsidiaries and affiliates ("PDG" or the "Company"). This Teaser is being provided solely to assist the recipient in determining whether it wishes to proceed with conducting its own due diligence investigation of the Company and a potential transaction involving the Company (the "Transaction"). The Company does not intend for this Teaser to form the sole basis of any Transaction decision. The recipient should conduct its own investigation and analysis of the Company in connection with any potential Transaction.

The Company does not make any representation or warranty, express or implied, or accept any responsibility or liability for the accuracy or completeness of this Teaser or any other written or oral information that the Company or any other person makes available to any recipient. The Company does not make any representation or warranty as to the achievement or reasonableness of any projections, management estimates, prospects or returns. This Teaser speaks only as of the date of the information herein and the Company does not have any obligation to update or correct any information herein.

A Transaction with the Company involves a degree of risk. Any party to a Transaction should inquire into, independently investigate and consider such risks in its due diligence investigation before entering into a Transaction. This Teaser is confidential and by accepting this Teaser, the recipient agrees not to disclose, copy or distribute this Teaser or the information herein, without the Company's prior written consent.

Upon request, the recipient must return promptly all material provided by or on behalf of the Company (including this Teaser) without retaining any copies. The Company undertakes no obligation to provide the recipient with access to additional information and reserves the right, without advance notice, to negotiate with one or more prospective parties, to change the procedures for any Transaction, to terminate negotiations at any time prior to the signing of a binding agreement for a Transaction and to enter into such agreements with any other party.